CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors.

The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Charles River's new initiative specifically caters to early-stage biotechnology developers.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing...

Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts.

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Charles River Laboratories International, Inc. (NYSE:CRL ) Q3 2024 Earnings Conference Call November 6, 2024 9:30 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relatio...

CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wal...

Charles River Laboratories (CRL) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.72 per share a year ago.

Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients f...

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand.

Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Retrogenix® Non-Human Protein Library to support assessment of off-target binding, de-risk studies & aid model select...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules third-quarter 2024 earnings release and conference call.